Population Health Sciences, University of Bristol, Bristol, United Kingdom.
Center for Modeling, Planning and Policy Analysis, Avenir Health, Glastonbury, CT.
J Acquir Immune Defic Syndr. 2024 Jan 1;95(1S):e89-e96. doi: 10.1097/QAI.0000000000003326. Epub 2024 Jan 4.
Mortality rates for people living with HIV (PLHIV) on antiretroviral therapy (ART) in high-income countries continue to decline. We compared mortality rates among PLHIV on ART in Europe for 2016-2020 with Spectrum's estimates.
The AIDS Impact Module in Spectrum is a compartmental HIV epidemic model coupled with a demographic population projection model. We used national Spectrum projections developed for the 2022 HIV estimates round to calculate mortality rates among PLHIV on ART, adjusting to the age/country distribution of PLHIV starting ART from 1996 to 2020 in the Antiretroviral Therapy Cohort Collaboration (ART-CC)'s European cohorts.
In the ART-CC, 11,504 of 162,835 PLHIV died. Between 1996-1999 and 2016-2020, AIDS-related mortality in the ART-CC decreased from 8.8 (95% CI: 7.6 to 10.1) to 1.0 (0.9-1.2) and from 5.9 (4.4-8.1) to 1.1 (0.9-1.4) deaths per 1000 person-years among men and women, respectively. Non-AIDS-related mortality decreased from 9.1 (7.9-10.5) to 6.1 (5.8-6.5) and from 7.0 (5.2-9.3) to 4.8 (4.3-5.2) deaths per 1000 person-years among men and women, respectively. Adjusted all-cause mortality rates in Spectrum among men were near ART-CC estimates for 2016-2020 (Spectrum: 7.02-7.47 deaths per 1000 person-years) but approximately 20% lower in women (Spectrum: 4.66-4.70). Adjusted excess mortality rates in Spectrum were 2.5-fold higher in women and 3.1-3.4-fold higher in men in comparison to the ART-CC's AIDS-specific mortality rates.
Spectrum's all-cause mortality estimates among PLHIV are consistent with age/country-controlled mortality observed in ART-CC, with some underestimation of mortality among women. Comparing results suggest that 60%-70% of excess deaths among PLHIV on ART in Spectrum are from non-AIDS causes.
在高收入国家,接受抗逆转录病毒疗法(ART)的艾滋病毒感染者(PLHIV)的死亡率继续下降。我们比较了欧洲 2016-2020 年接受 ART 的 PLHIV 的死亡率与 Spectrum 的估计值。
Spectrum 中的艾滋病影响模块是一个分区 HIV 流行模型,与人口预测模型相结合。我们使用为 2022 年 HIV 估计数而开发的国家 Spectrum 预测来计算接受 ART 的 PLHIV 的死亡率,调整了从 1996 年到 2020 年开始接受 ART 的 PLHIV 的年龄/国家分布,以适应抗逆转录病毒治疗队列合作(ART-CC)的欧洲队列。
在 ART-CC 中,有 11504 名 PLHIV 死亡。在 1996-1999 年至 2016-2020 年期间,ART-CC 中的艾滋病相关死亡率从每 1000 人年 8.8(95%CI:7.6 至 10.1)下降到 1.0(0.9 至 1.2),从每 1000 人年 5.9(4.4 至 8.1)下降到 1.1(0.9 至 1.4)。男性和女性的非艾滋病相关死亡率分别从每 1000 人年 9.1(7.9 至 10.5)下降到 6.1(5.8 至 6.5)和从每 1000 人年 7.0(5.2 至 9.3)下降到 4.8(4.3 至 5.2)。调整后的 Spectrum 中男性的全因死亡率与 2016-2020 年的 ART-CC 估计值相近(Spectrum:7.02-7.47 人年),但女性的死亡率约低 20%(Spectrum:4.66-4.70)。与 ART-CC 的艾滋病特异性死亡率相比,Spectrum 中女性的调整后超额死亡率高出 2.5 倍,男性高出 3.1-3.4 倍。
Spectrum 中 PLHIV 的全因死亡率估计值与 ART-CC 中年龄/国家对照死亡率一致,女性死亡率略有低估。比较结果表明,Spectrum 中接受 ART 的 PLHIV 中 60%-70%的超额死亡是由非艾滋病原因造成的。